Keyphrases
Circulating Tumor DNA (ctDNA)
100%
Minimal Residual Disease
100%
Non-small Cell Lung Cancer Patients
75%
Tumor-agnostic
68%
Lung Cancer Patients
50%
DNA Sequencing
50%
Plasma Samples
41%
Curative Treatment
33%
Recurrence-free Survival
29%
Short-term Recurrence
29%
Tumor Recurrence
27%
Curative Intent
25%
Disease Analysis
16%
Recurrence Prediction
16%
Blood Samples
16%
Deep Sequencing
14%
Commercially Available
14%
Log-rank Test
12%
Fisher's Exact Test
12%
DNA Detection
8%
Sequence Method
8%
Subgroup Analysis
8%
Clinical Validity
8%
Optimal Timing
8%
Clinical Benefit
8%
Recurrent Disease
8%
Non-small Cell Lung Cancer (NSCLC)
8%
Treatment-seeking Sample
8%
CAPP-Seq
6%
Contrast Detection
6%
Second Check
6%
Commercially Available Kit
6%
Residual Disease
6%
Consolidation Therapy
6%
DNA Analysis
6%
Transferability
6%
Retrospective Analysis
6%
Non-associated
6%
Prognostic Value
6%
Pharmacology, Toxicology and Pharmaceutical Science
Circulating Tumor DNA
100%
Minimal Residual Disease
100%
Non Small Cell Lung Cancer
78%
Neoplasm
71%
Lung Cancer
50%
Recurrent Disease
32%
Recurrence Free Survival
30%
Biological Marker
30%
Tumor Recurrence
29%
Medicine and Dentistry
Minimal Residual Disease
50%
Circulating Tumor DNA
50%
Lung Cancer
50%
Non Small Cell Lung Cancer
28%
Tumor Recurrence
21%
Neoplasm
21%
Fisher Exact Test
14%
Biological Marker
14%
Recurrence Free Survival
14%
Log Rank Test
14%
Recurrent Disease
7%
DNA Determination
7%
